PCSK9 inhibition 2018: riding a new wave of coronary prevention

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a hepatic enzyme that regulates the low-density lipoprotein cholesterol (LDL-c) receptor and thus circulating LDL-c levels. With overwhelming evidence now supporting the reduction in LDL-c to lower the risk of cardiovascular disease, PCSK9 inhibitors represent an important therapeutic target, particularly in high-risk populations. Here, we summarise and update the science of PCSK9, including its discovery and the development of various inhibitors, including the now approved monoclonal antibodies. In addition, we summarise the clinical applications of PCSK9 inhibitors in a range of patient populations, as well as themajor randomised controlled trials investigating their use in coronary prevention.

Original languageEnglish
Pages (from-to)205-224
Number of pages20
JournalClinical Science
Volume133
Issue number2
DOIs
Publication statusPublished - 31 Jan 2019

Cite this